Access TOC
Download Data
November 2024
The global antibody drug conjugate (ADC) market size was estimated at US$ 11.32 billion in 2023 and is projected to grow US$ 27.37 billion by 2033, rising at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. The rising number of cancer cases and the rising need for safe, efficient medications are anticipated to fuel market expansion.
Unlock Infinite Advantages: Subscribe to Annual Membership
Typically, an antibody-drug conjugate (ADC) is made up of a cytotoxic drug and a monoclonal antibody (mAb) that have been covalently linked by a chemical linker. The market for antibody drug conjugates is expanding as a result of its ability to combine the benefits of highly potent killing and highly specific targeting to accurately and effectively eradicate cancer cells. The antibody drug conjugate market has emerged as a center for anticancer drug research and development.
Artificial Intelligence (AI) is set to revolutionize the Antibody Drug Conjugate (ADC) market by enhancing efficiency, precision, and innovation. AI algorithms can expedite the drug discovery process by analyzing vast datasets to identify potential antibody-drug combinations that are most likely to succeed. This reduces the time and cost associated with traditional trial-and-error methods. Additionally, AI can optimize the design of ADCs by predicting how different molecular structures will interact with target cells, thus improving efficacy and minimizing side effects.
In clinical trials, AI-driven analytics can predict patient responses, allowing for more personalized treatment plans and improving overall outcomes. AI can also streamline manufacturing processes by monitoring production in real-time, identifying potential issues before they become significant problems, and ensuring consistent quality.
AI's capability to process and analyze large volumes of biomedical literature and patient data can uncover new insights and trends that inform future research and development. By integrating AI into the ADC market, companies can accelerate innovation, reduce costs, and improve patient outcomes, ultimately driving market growth and enhancing the therapeutic potential of antibody-drug conjugates.
| Company Name | AbbVie |
| Headquarters | Illinois, U.S. |
| Recent Launch | In May 2024, during the American Society of Clinical Oncology (ASCO) Annual Meeting, which took place from May 31 to June 4, 2024, AbbVie presented three oral talks showcasing their novel antibody-drug conjugate (ADC) technology. Targeting distinct protein biomarkers that are overexpressed in different types of tumors, such as seizure-related homolog 6 protein (SEZ6) and c-Met (MET protein), is the goal of AbbVie's ADCs. Administering powerful drugs known as 'payloads' to the tumor, anticancer drug delivery systems (ADCs) use these biomarkers as possible targets. |
| Company Name | AstraZeneca |
| Headquarters | Cambridge, United Kingdom |
| Recent Launch | In May 2024, to increase the availability of its range of antibody-drug conjugates (ADCs) throughout the world, AstraZeneca plans to construct a $1.5 billion production plant in Singapore. Through the use of a specific antibody, ADCs are next-generation therapies that directly deliver extremely effective anti-cancer medicines to cancer cells. AstraZeneca's first end-to-end ADC production site will be a planned greenfield plant with funding from the Singapore Economic Development Board (EDB). It will completely incorporate every stage of the manufacturing process at a commercial scale. |
Thanks to advancements in molecular biology techniques, site-specific antibody conjugation is being added to ADCs to boost their therapeutic efficacy. Genetically created antibodies are possible. Efforts are still being made to optimize the design of antibodies, linkers, and cytotoxic drug payloads in the particularly active field of ADC development research and development.
For instance,
With twelve compounds in clinical use at the moment, ADCs are a fast-growing family of anti-cancer medications. Even with recent advancements, severe toxicities and negative risk-benefit profiles cause many ADCs to fail throughout clinical development. A significant portion of treated patients need dose reduction, treatment delays, or therapy withdrawal because of unacceptable ADC-associated toxicity, even for those ADCs that have been licensed for clinical use.
Personalized ADCs might become a reality in the future when technology develops even further. Based on the patient's tumor antigens and other features, we might be able to create the best possible antibody, linker, and payload. "Smart chemotherapy" is what ADCs are. ADCs have the potential to replace chemotherapy in all present settings, and there are a tonne of opportunities when it comes to customized ADCs.
The breast cancer segment dominated the antibody drug conjugate market in 2023. The management of breast cancer has been greatly impacted by the multiple advancements and approvals for cancer treatments brought about by the explosive expansion in ADC research. Notably, the development of ADCs has advanced significantly in the field of breast cancer; the first approved ADC for solid tumors was T-DM1.
There is an increasing need for antibody-drug conjugates due to the rising incidence of breast cancer. The World Health Organization estimates that 670,000 people died worldwide, and 2.3 million women received a breast cancer diagnosis in 2022. Women get breast cancer in about 99% of cases, while men get breast cancer in 0.5–1% of cases.
The blood cancer segment is expected to grow at the fastest rate during the forecast period. Only one ADC has a solid tumor indication as of yet; the other three are approved by the FDA to treat hematological malignancies. Blood malignancies are less difficult to treat with ADCs due to their less restrictive tumor selectivity and easier access to the targeted cancer cells compared to solid tumors. These are the two key reasons for the improved success rate of this approach. Currently undergoing clinical trials are numerous ADCs, five of which have been approved to treat breast cancer or blood cancer.
The Kadcyla segment held the largest share of the antibody drug conjugate market in 2023. An antibody-drug combination called Kadcyla is designed to provide strong chemotherapy to HER2-positive cancer cells directly, possibly reducing harm to healthy organs in the process. In more than 100 nations, including the US and the EU, Kadcyla is authorized to be used as a single agent in the treatment of humans. Recurrences of the malignancy may be less common with trastuzumab emtansine, according to the study: Recurrences occurred in roughly 13 out of 100 patients who received trastuzumab emtansine and in about 23 out of 100 patients who received trastuzumab.
For instance,
The Enhertu segment is estimated to grow at the fastest CAGR during 2024-2033. Enhertu has also received FDA approval for the treatment of adult HER2-positive non-small cell lung cancer (NSCLC). Enhertu targets HER2-positive breast cancer that has been treated with an anti-HER2 medication, as well as HER2-low breast cancer that has been treated with chemotherapy, as well as unresectable (not removable with surgery) and metastatic breast cancer.
For instance,
The HER2 segment held the largest antibody drug conjugate market share in 2023. Recently, significant progress has been achieved in the development of antibody-conjugation techniques, resulting in the creation of a novel class of potent drugs known as antibody-drug conjugates (ADCs) that target HER2. These molecules have completely changed the treatment landscape for breast cancer. Transtuzumab-emtansine and trastuzumab-deruxtecan, two HER2-targeting ADCs, have increased overall survival with manageable side effects in the second and third-line settings. In preclinical and clinical research, several HER2-targeting ADCs that make use of cutting-edge technological developments in the conceptualization of the antibody, linker, and/or payload have demonstrated promising activity. Some of these are currently being assessed in bigger clinical trials.
For instance,
The CD22 segment is anticipated to grow at the fastest rate during the forecast period. A unique cell surface sialoglycoprotein found on B-cells, CD22 controls B-cell growth and function. It is, therefore, a promising therapeutic target for B-cell cancers and autoimmune diseases. Numerous treatments, such as monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, chimeric antigen receptor T cells, and bispecific antibodies, have been developed to target CD22. In this article, we go over the biology of CD22 and the important treatments that target it in lymphoid cancers. Additionally, autoimmune disorders like Sjogren syndrome and systemic lupus erythematosus have been linked to targeting CD22.
The cleavable linker segment held the dominant share of the antibody drug conjugate market in 2023. An essential component of antibody-drug conjugates' effectiveness is cleavable linkers. They release cytotoxins from ADCs in a targeted manner by making use of the innate characteristics of tumor cells. They stay steady for a considerable amount of time in the bloodstream. Clever linkers, including inotuzumab ozogamicin (Besponsa) and brentuximab vedotin (Adcetris), are used by more than 80% of the clinically authorized ADCs9.
North America dominated the antibody drug conjugate market by 53% in 2023. A number of well-funded start-ups and small businesses that provide antibody-drug conjugate with sophisticated linkers and more powerful warheads have emerged in recent years. The bulk of these businesses are headquartered in North America. Furthermore, ADC therapies for cancer have been actively reviewed and approved by the FDA. The use of antibody drug conjugates will be fueled by the U.S.'s rising cancer incidence rate.
Globally and in the U.S., cancer has a profound effect on society. It is predicted that in 2024, there will be 2,001,140 new instances of cancer identified in the U.S. and 611,720 deaths from the illness. An estimated 18.1 million Americans had survived cancer as of January 2022. By 2032, it is anticipated that there will be 22.5 million cancer survivors worldwide. It is projected that 14,910 kids and teenagers between the ages of 0 and 19 will receive a cancer diagnosis in 2024, and 1,590 of them will pass away from the illness. In 2020, the U.S. is expected to spend $208.9 billion on cancer care on a national level. Costs will probably rise in the coming years as the population ages, and the number of cancer cases rises.
By Application
By Product
By Target
By Technology
By Region
November 2024
November 2024
October 2024
October 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts